Nivolumab is a human immunoglobulin G4 anti‐programmed cell death 1 (PD‐1) antibody, which was approved as monotherapy for the second‐line treatment of advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.